New insider activity at Phathom Pharmaceuticals ( (PHAT) ) has taken place on July 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent transaction, CAO Robert Charles Breedlove sold 1,692 shares of Phathom Pharmaceuticals stock, amounting to a total value of $14,145.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals faces significant financial challenges with ongoing losses and negative equity. However, recent FDA approvals and strategic cost management initiatives provide a positive outlook. Technical indicators and earnings call insights suggest potential growth, but valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
YTD Price Performance: 13.51%
Average Trading Volume: 2,773,940
Technical Sentiment Signal: Hold
Current Market Cap: $581.6M